UNSPSC 41181519: Complement c2inhibitor (inactivator) immunological test system

In this classification, a Complement c2inhibitor (inactivator) immunological test system is a device that consists of the reagents used to identify by immunochemical techniques Complement c2inhibitor (inactivator). US FDA regulates Complement c2inhibitor (inactivator) immunological test system under 21 CFR 866.5250 and under FDA product code DBA.

UNSPSC 41181519 Complement c2inhibitor (inactivator) immunological test system is a Commodity code, but the recent state and local opportunities tagged under it do not reflect immunological testing services or complement system analysis. Instead, the posted solicitations span laboratory equipment repair and maintenance, spectrophotometer procurement, insulating oil testing for electric utilities, fire station construction inspection, water treatment plant well drilling, meter test boards, and electric vehicle charger repair—none of which align with the code's stated scope of immunological test systems for complement c2 inactivator analysis. Marion County, Oregon issued ITB SO1814-26 (due July 24, 2026) for laboratory testing services and phlebotomy for Adults in Custody, which covers specimen collection and general laboratory draws rather than specialized immunological testing. The Texas Department of State Health Services solicited equipment maintenance (IFB HHS0017421, due July 6, 2026) for laboratory washers and sterilizers at its South Texas Laboratory, with historical annual values ranging from $25,050 to $40,000. The City of Tampa procured a replacement spectrophotometer (RFQ 26-P-00372) for its waste-to-energy facility rather than immunological test equipment. Lubbock Power & Light requested proposals for insulating oil testing laboratory services (RFP 713126ELD, due July 22, 2026) focused on transformer diagnostics under IEEE and IEC standards, requiring ISO/IEC 17025 accreditation and LIMS integration with delta-X TOA4 compatibility.

The code shows no recent state and local procurement activity aligned with immunological test systems or complement pathway analysis. The issuing bodies—county health departments, state health agencies, utilities, and municipal facilities—are procuring general laboratory services, equipment maintenance, and specialized testing for non-immunological applications. The geographic spread includes Oregon, Texas, and Florida in the recent visible activity, but the mismatch between the code's nominal scope and actual solicitations suggests this commodity code either receives sparse true activity or has been misapplied to unrelated laboratory and testing procurements in the source data. Vendors pursuing complement c2inhibitor immunological testing systems should verify directly with public health labs and clinical diagnostic programs rather than relying on this code's recent posting history.